

Comparative Analysis of Small Molecules and Histone Substrate Analogues as LSD1 Lysine Demethylase Inhibitors

Jeffrey C. Culhane,[†] Dongqing Wang,[‡] Paul M. Yen,^{‡,§} and Philip A. Cole^{*,†}

Department of Pharmacology and Molecular Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, Department of Medicine, Johns Hopkins Bayview Medical Center, Baltimore, Maryland 21224, and Cardiovascular and Metabolic Diseases Program, Duke-NUS Graduate Medical School, Singapore 169857

Received November 25, 2009; E-mail: pcole@jhmi.edu

Abstract: LSD1 is a flavin-dependent histone demethylase that oxidatively removes methyl groups from Lys-4 of histone H3. LSD1 belongs to the amine oxidase enzyme superfamily which utilize molecular oxygen to transform amines to imines that are hydrolytically cleaved to formaldehyde. In prior studies, it has been shown that monoamine oxidase inhibitory scaffolds such as propargylamines and cyclopropylamines can serve as mechanism-based inactivators of LSD1. Propargylamine-histone H3 peptide analogues are potent LSD1 inhibitors, whereas small molecule antidepressant MAO acetylenic inhibitors like pargyline do not inhibit LSD1. In contrast, the small molecule MAO cyclopropylamine inhibitor tranlylcypromine is a time-dependent LSD1 inhibitor but *exo*-cyclopropylamine-peptide substrate analogue is not. To provide further insight into small molecule versus peptide relationships in LSD1 inhibition, herein we further our analysis of warheads in peptide scaffolds to include the chlorovinyl, *endo*-cyclopropylamine, and hydrazine-functionalities as LSD1 inactivators. We find that chlorovinyl-H3 is a mechanism-based LSD1 inactivator whereas *endo*-cyclopropylamine-H3 does not show time-dependent inactivation. The hydrazine-H3 was shown to be the most potent LSD1 suicide inhibitor yet reported, more than 20-fold more efficient in inhibiting demethylation than propargylamine-H3 derivatives. We re-explored MAO antidepressant agent phenelzine (phenethylhydrazine), previously reported to be a weak LSD1 inhibitor, and found that it is far more potent than previously appreciated. We show that phenelzine can block histone H3K4Me demethylation in cells, validating it as a pharmacologic tool and potential lead structure for anticancer therapy.

Post-translational modification (PTM) of histones on lysines regulates gene expression by remodeling chromatin and is a central focus of epigenetic studies.^{1,2} Among the many PTMs that reversibly modify chromatin, lysine methylation provides for a rich array of biological readouts.^{3,4} For example, methylation of Lys-4 of histone H3 is a mark of gene activation, whereas Lys-9 methylation is more often associated with gene silencing. The relatively recent discovery of histone lysine demethylases has helped round out our understanding of the factors that control methyl-Lys stability.^{5,6} Included among the histone demethylases are the flavin-dependent enzymes LSD1 and LSD2 and the iron-dependent Jmj catalysts.⁵⁻⁷

LSD1 is a member of the amine oxidase superfamily and utilizes a noncovalently bound FAD cofactor in the oxidative

removal of methyl groups, specifically from Lys-4 of histone H3.^{5,8} The catalytic cycle of methyl removal produces a molecule each of formaldehyde and H₂O₂ while consuming O₂ (Scheme 1).^{5,8} Dictated by the inherent limitations of the flavin chemistry, LSD1 can only function in the removal of the mono and dimethyl species of Lys-4.⁵ LSD1 functions as a transcriptional repressor and is a component of various transcriptional corepressor complexes that often include HDAC1/2 and CoREST.⁹⁻¹² In addition to processing histone proteins, LSD1 can demethylate H3-tail peptides, requiring at least 15 amino acid residues for efficient demethylation.^{5,13} Inhibitors of LSD1 would be expected, in general, to reactivate gene expression of silenced genes, which might have utility in the treatment of cancer and other diseases.^{14,15} Such compounds could for example be synergistic with HDAC inhibitors.^{14,15}


[†] Johns Hopkins University School of Medicine.

[‡] Johns Hopkins Bayview Medical Center.

[§] Duke-NUS Graduate Medical School.

- (1) Taverna, S. D.; Li, H.; Ruthenburg, A. J.; Allis, C. D.; Patel, D. J. *Nat. Struct. Mol. Biol.* **2007**, *14*, 1025–1040.
- (2) Cole, P. A. *Nat. Chem. Biol.* **2008**, *4*, 590–597.
- (3) Martin, C.; Zhang, Y. *Nat. Rev. Mol. Cell. Biol.* **2005**, *6*, 838–849.
- (4) Kouzarides, T. *Cell* **2007**, *282*, 15040–15047.
- (5) Shi, Y.; Lan, F.; Matson, C.; Mulligan, P.; Whetstone, J. R.; Cole, P. A.; Casero, R. A.; Shi, Y. *Cell* **2004**, *119*, 941–953.
- (6) Tsukada, Y.; Fang, J.; Erdjument-Bromage, H.; Warren, M. E.; Borchers, C. H.; Tempst, P.; Zhang, Y. *Nature* **2006**, *439*, 811–816.
- (7) Karytinis, A.; Forneris, F.; Profumo, A.; Ciossani, G.; Battaglioli, E.; Binda, C.; Mattevi, A. *J. Biol. Chem.* **2009**, *284*, 17775–17782.

- (8) Binda, C.; Mattevi, A.; Edmonson, D. E. *J. Biol. Chem.* **2002**, *277*, 23973–23976.
- (9) Hakimi, M. A.; Dong, Y.; Lane, W. S.; Speicher, D. W.; Shiekhattar, R. *J. Biol. Chem.* **2003**, *278*, 7234–7239.
- (10) Humphrey, G. W.; Wang, Y.; Russanova, V. R.; Hirai, T.; Qin, J.; Nakatani, Y.; Howard, B. H. *J. Biol. Chem.* **2001**, *276*, 6817–6824.
- (11) Shi, Y.; Sawada, J.; Sui, G.; Affar el, B.; Whetstone, J. R.; Lan, F.; Ogawa, H.; Luke, M. P.; Nakatani, Y.; Shi, Y. *Nature* **2003**, *422*, 735–738.
- (12) You, A.; Tong, J. K.; Grozinger, C. M.; Schreiber, S. L. *Proc. Natl. Acad. Sci. U.S.A.* **2001**, *98*, 1454–1458.
- (13) Forneris, F.; Binda, C.; Vanoni, M. A.; Battaglioli, E.; Mattevi, A. *J. Biol. Chem.* **2005**, *280*, 41360–41365.

Scheme 1. Catalytic Cycle of Flavin Mediated Amine Oxidation^a

^a Oxidation of the amine to an iminium ion, with concurrent reduction of the flavin enables attack by a closely held water molecule. Collapse of the hemiaminal to a carbonyl yields formaldehyde and amine. Reduced flavin is re-oxidized by molecular oxygen, generating a molecule of hydrogen peroxide.

The flavin-dependent amine oxidase family of enzymes has been intensively studied over the past 50 years as clinical targets for human diseases.¹⁶ In particular, the monoamine oxidases, MAO-A and MAO-B, play key roles in the clearance of neurotransmitters.^{16–18} Selective MAO-A/B suicide inactivators have enjoyed decades of clinical success in the treatment of major depression and neurodegenerative disorders such as Parkinson's disease.^{16–18} Since LSD1 and MAO-A/B share a common mechanism for the oxidative cleavage of the unactivated nitrogen–carbon bonds of their substrates, many of the known MAO inactivators have been tested as LSD1 inhibitors.¹⁴ Tranylcypromine, a cyclopropylamine containing small molecule, has been characterized as an LSD1 inactivator through biochemical, spectroscopic, and crystallographic procedures.^{14,19,20} The hydrazine-containing MAO inhibitor and antidepressant phenelzine has also been reported to be a weak LSD1 inhibitor.¹⁴ On the other hand, pargyline, a propargylamine containing small molecule initially suggested to be an LSD1 inhibitor, has failed in subsequent studies to appreciably inactivate LSD1.^{13,14}

Interestingly, the propargylamine functionality in the context of a histone H3-21 peptide (**1**) has yielded potent time- and concentration-dependent inactivation of LSD1 (Figure 1).^{21–23} Characterization of the inactivation by **1** and its *N*-methyl analogue **2** by kinetic, spectroscopic, and crystallographic studies have revealed key mechanistic and structural information about the nature of inactivation and substrate recognition.^{21–23} In particular, an X-ray crystal structure of LSD1 inactivated by **2** has provided a model for histone H3 substrate recognition.²³ These studies have established that MAO inhibitor functional-




Figure 1. Structures of evaluated LSD1 inhibitors and inactivators.


ities can target LSD1 but leave open the range of warheads and the contextual relationship to substrate analogues that can inhibit this enzyme. In this study, we investigate other known MAO-A/B inactivator motifs for incorporation into histone H3-21 peptides in the search for increasingly potent inactivators of LSD1. We compare and contrast the behavior of small molecules versus peptide analogues containing inhibitory warheads. Importantly, we identify the hydrazine motif as the most potent LSD1 inhibitor functionality in the context of peptides and small molecules.

Results and Discussion

Chlorovinyl-H3 Peptide Analogue Synthesis and LSD1 Inhibition. The 3-chloroallylamine functionality has the ability to inactivate flavin-dependent amine oxidases,^{24,25} and we

- (14) Lee, M. G.; Wynder, C.; Schmidt, D. M.; McCafferty, D. G.; Shiekhhattar, R. *Chem. Biol.* **2006**, *13*, 563–567.
- (15) Huang, Y.; Greene, E.; Stewart, T. M.; Goodwin, A. C.; Baylin, S. B.; Woster, P. M.; Casero, R. A., Jr. *Proc. Natl. Acad. Sci. U.S.A.* **2007**, *104*, 8023–8028.
- (16) Edmondson, D. E.; Mattevi, A.; Binda, C.; Li, M.; Hubálek, F. *Curr. Med. Chem.* **2004**, *11*, 1983–1993.
- (17) Yu, P. H. *Gen. Pharmacol.* **1994**, *25*, 1527–1539.
- (18) Goodman, W. K.; Charney, D. S. *J. Clin. Psychiatry.* **1985**, *46*, 6–24.
- (19) Schmidt, D. M.; McCafferty, D. G. *Biochemistry* **2007**, *46*, 4408–4416.
- (20) Yang, M.; Culhane, J. C.; Szewczuk, L. M.; Jalili, P.; Ball, H. L.; Machius, M.; Cole, P. A.; Yu, H. *Biochemistry* **2007**, *46*, 8058–8065.
- (21) Culhane, J. C.; Szewczuk, L. M.; Liu, X.; Da, G.; Marmorstein, R.; Cole, P. A. *J. Am. Chem. Soc.* **2006**, *128*, 4536–4537.
- (22) Szewczuk, L. M.; Culhane, J. C.; Yang, M.; Majumdar, A.; Yu, H.; Cole, P. A. *Biochemistry* **2007**, *46*, 6892–6902.
- (23) Yang, M.; Culhane, J. C.; Szewczuk, L. M.; Gocke, C. B.; Brautigam, C. A.; Tomchick, D. R.; Machius, M.; Cole, P. A.; Yu, H. *Nat. Struct. Mol. Biol.* **2007**, *14*, 535–539.

Scheme 2. Synthesis of Peptide Inhibitors *cis*-3-Chloroallyl-Lys-4 H3-21 (**3**), *trans*-3-Chloroallyl-Lys-4 H3-21 (**4**) and Hydrazino-Lys-4 H3-21 (**18**)^a



^a Incorporation of Fmoc-hydroxynorleucine in the four position of H3-21 yields the resin bound peptide. Mesylation of the alcohol while on bead, followed by trifluoroacetic acid cleavage and RP-HPLC purification provides mesyl-Lys-4 H3-21 peptide **5**. Displacement of the mesylate by *cis*- or *trans*-3-chloroallylamine or hydrazine yields the desired peptide inhibitors. Single letter amino acid abbreviations represent the H3-21 sequence.

therefore sought to generate H3-chlorovinyl analogues **3** and **4**. For this purpose, we prepared *cis*-3-chloroallylamine hydrochloride from commercially available *cis*-1,3-dichloropropene utilizing the Gabriel synthetic approach.²⁵ The corresponding *trans*-3-chloroallylamine hydrochloride was generated in a similar fashion from commercially available *rac*-1,3-dichloropropene followed by selective precipitation.²⁵ Peptide analogues **3** and **4** were synthesized utilizing our previously reported strategy.²¹ Briefly, a 21 amino acid *N*-terminal histone H3 tail peptide was constructed on solid support incorporating an oxalogue of lysine, 6-hydroxynorleucine,²¹ at the fourth position. Following mesylation of the alcohol, the peptide was cleaved from the resin and universally deprotected, allowing for reverse phase high performance liquid chromatography (RP-HPLC) purification of the mesylate peptide (**5**). Displacement of the mesylate with small molecule amines afforded the desired peptides in 40–50% yield (Scheme 2).

Peptides **3** and **4** were assayed against recombinant GST-LSD1 utilizing a horseradish peroxidase coupled assay for the detection of H₂O₂ produced in the demethylase catalytic cycle.²¹ *cis*-3-Chloroallyl-Lys-4 H3-21 (**3**) and *trans*-3-chloroallyl-Lys-4 H3-21 (**4**) both displayed time- and concentration-dependent inactivation of LSD1 with $K_{i(\text{inact})} = 0.955 \pm 0.15$ and $0.763 \pm 0.12 \mu\text{M}$, and $k_{\text{inact}} = 0.545 \pm 0.038$ and $0.128 \pm 0.0087 \text{ min}^{-1}$, respectively (Figure 2, Table 1). It has been hypothesized that the chlorovinyl mechanism of inactivation of MAO is similar to that of a propargylamine inactivator.²⁴ We propose, in analogy to previous studies on MAOs, that oxidation of **3** and **4** produces α,β -unsaturated iminium electrophiles that are capable of Michael addition with a nearby nucleophile. The presence of

the chloride as a leaving group allows for the generation of a conjugated diamine linker (Scheme 3). The 4-fold difference in the inactivation rate constants for the *cis* (**3**) versus *trans* (**4**) isomer may be related to altered oxidation rates or follow-on nucleophilic attack differences that stem from the steric and spatial orientation of the chloride atom in the active site of the enzyme. The efficiency of inactivation ($k_{\text{inact}}/K_{i(\text{inact})}$) of LSD1 by **3** is similar to that of the propargylamine compound **1** and within 5-fold of the $k_{\text{inact}}/K_{i(\text{inact})}$ of the more potent *N*-methylpropargylamine peptide **2** (Figure 1, Table 1).

To further investigate the inactivation processes for **3** and **4**, we employed UV–visible spectroscopy to characterize possible flavin adducts, as seen previously with compounds **1** and **2**.^{21–23} LSD1-bound FAD has two characteristic absorption maxima in the 350–550 nm range, attributed to the fully oxidized flavin and the one electron reduced semiquinone form.²⁶ As with **1**, treatment of LSD1 with inactivator **3** or **4** leads to the near bleaching of the flavin spectrum. The *cis* isomer (**3**) results in a newly formed maximum at 383 nm, while the *trans* isomer (**4**) induces a new maximum at a wavelength less than 350 nm (Figure 3). It is possible that these spectroscopic shifts correspond to inhibitor-flavin adducts with different stereochemistry.

The FAD molecule of LSD1 is noncovalently bound. Inactivator-FAD adducts can therefore be isolated from the protein prior to analysis by MALDI-TOF mass spectrometry.^{20–23} Mass spec analysis of denatured **3** or **4**-inactivated LSD1 showed peaks at $m/z = 3077$, corresponding to the mass of the peptide and the FAD following the loss of the chloride atom, as proposed in Scheme 3 (Figure 4). Additionally, for both inactivation reactions, a peak corresponding to H3-21 peptide is noted at $m/z = 2255$, this degradation product may be

(24) Rando, R. R.; Eigner, A. *Mol. Pharmacol.* **1997**, *13*, 1005–1013.

(25) Jeon, H. B.; Sayre, L. M. *Biochem. Biophys. Res. Commun.* **2003**, *304*, 788–794.

(26) Woo, J. C. G.; Silverman, R. B. *Biochem. Biophys. Res. Commun.* **1994**, *202*, 1574–1578.





Figure 2. Time- and concentration-dependent inactivation of GST-LSD1 by *cis*-3-chloroallyl-Lys-4 H3-21 (**3**) and *trans*-3-chloroallyl-Lys-4 H3-21 (**4**). (A and C) Steady-state progress curves obtained for the inactivation of LSD1 in the presence of concentrations of **3** ranging from 0 to 28.8 μM and concentrations of **4** ranging from 0 to 27.2 μM . (B and D) Rate constants (k_{obs}) for the time-dependent inactivation of LSD1 by **3** and **4** were extracted from the steady-state data in (A) and (C) by single exponential fits and analyzed by the method of Kitz and Wilson to determine k_{inact} and $K_{\text{i(inact)}}$ values.

Table 1. Kinetics of Evaluated GST-LSD1 Inhibitor and Inactivator Peptides and Small Molecules^a

| Inhibitor/Inactivator | $K_{\text{i(inact)}}$ (μM) | $k_{\text{(inact)}}$ (min^{-1}) | $k_{\text{(inact)}/K_{\text{i(inact)}}$ ($\mu\text{M}^{-1}\text{min}^{-1}$) | K_{i} (μM) |
|---|---|--|---|----------------------------------|
| propargyl-Lys-4 H3-21 (1) | 0.775 ± 0.16 | 0.304 ± 0.033 | 0.392 ± 0.0088 | — |
| <i>N</i> -methylpropargyl-Lys-4 H3-21 (2) | 0.107 ± 0.057 | 0.208 ± 0.068 | 1.94 ± 0.34 | — |
| <i>cis</i> -3-chloroallyl-Lys-4 H3-21 (3) | 0.955 ± 0.15 | 0.545 ± 0.038 | 0.571 ± 0.0062 | — |
| <i>trans</i> -3-chloroallyl-Lys-4 H3-21 (4) | 0.763 ± 0.12 | 0.128 ± 0.0087 | 0.168 ± 0.0018 | — |
| <i>exo</i> -cyclopropyl-Lys-4 H3-21 (6) | — | — | — | 2.70 ± 0.74 |
| <i>endo</i> -cyclopropyl-Lys-4 H3-21 (7) | — | — | — | 6.11 ± 0.86 |
| <i>endo</i> -dimethylcyclopropyl-Lys-4 H3-21 (8) | — | — | — | 24.2 ± 2.7 |
| hydrazino-Lys-4 H3-21 (18) | 0.00435 ± 0.00086 | 0.247 ± 0.018 | 56.8 ± 0.82 | — |
| tranylcypromine | 357 ± 120 | 0.542 ± 0.094 | 0.00152 ± 0.000089 | — |
| phenelzine | 17.6 ± 2.8 | 0.955 ± 0.085 | 0.0543 ± 0.00077 | — |

^a Data for compounds **1**, **2**, **6**, and tranylcypromine have been obtained previously.^{20–23}

Scheme 3. Proposed Mechanism of Inactivation of GST-LSD1 by *cis*-3-Chloroallyl-Lys-4 H3-21 (**3**)^a



^a Flavin mediated two electron oxidation of **3** yields an α,β -unsaturated iminium species. Pathway (a) Nucleophilic attack by the N^5 of the reduced flavin leads to an α -chloro enamine intermediate. Subsequent loss of the chloride atom forms the conjugated diamine linked **3-FAD** conjugate. Pathway (b) Nucleophilic attack on the activated species by a water molecule leads to H3-21 peptide degradation product. Pathway (c) Nucleophilic attack on the activated species by a nucleophile contained in the peptide leads to a cyclic peptide degradation product.

generated from an active site water molecule attacking the oxidatively activated iminium species at the α carbon as shown in Scheme 3, path b. Another potential degradation peak is also

noted at $m/z = 2290$. The mass of the product corresponds to the loss of HCl from the oxidized intermediates produced from **3** or **4**. It is formally possible that after the activation of **3** and




Figure 3. Spectroscopic analysis of *cis*- or *trans*-3-chloroallyl-Lys-4 H3-21 (**3** and **4**) treated GST-LSD1. UV/vis spectra of native LSD1 (blue) shows the distinctive two maxima of the fully oxidized flavin and the one electron reduced semiquinone. (A) LSD1 treated with **3** leads to a shift in the absorbance to a new maximum at 383 nm. (B) LSD1 treated with **4** leads to a shift in the absorbance to a new maximum less than 350 nm.

4 by LSD1 an intramolecular cyclization of the peptide thru Michael addition, potentially within or outside the active site, leads to the degradation of the inactivator, as shown in Scheme 3, path c. Consistent with these degradation mechanisms of the inactivator, only a minor peak in the mass spectrum corresponding to the mass of peptide **3** or **4** is observed after LSD1 treatment. Taken together, these studies support an inactivation mechanism involving flavin attack on the conjugated imine as proposed in Scheme 3. It is difficult to obtain precise partition ratios, however, because of the challenge in separating and quantifying the various enzymatic products by HPLC.

Endo-Cyclopropyl-H3 Synthesis and LSD1 Inhibition Analysis. The small molecule tranlycypromine displays moderately potent time- and concentration-dependent inactivation of LSD1 (Table 1).²⁰ In contrast, an H3-21 peptide that incorporated an *exo*-cyclopropyl-Lys-4 functionality (**6**) was found to be a reversible inhibitor (estimated $K_i = 2.70 \pm 0.74 \mu\text{M}$), but did not inactivate LSD1 (Figure 1, Table 1).²² It can be rationalized that this result is due to steric clashes related to the bulky *exo*-cyclopropyl group of **6**. To explore this further, we synthesized the corresponding *endo*-cyclopropylamine containing peptides **7** and **8** which better mimic the structural arrangements found in tranlycypromine (Figure 1). To that end, an efficient synthesis of the Fmoc-*endo*-cyclopropyl-Lys(Boc)-OH (**9**) and Fmoc-*endo*-dimethylcyclopropyl-Lys-OH (**10**) monomers was designed for their direct incorporation during solid phase peptide synthesis. While previous syntheses exist for *endo*-cyclopropyl containing lysine residues,²⁷ our route maintains the proper four carbon chain between the peptide backbone and the epsilon nitrogen of lysine.

(27) Brandl, M.; Kozhushkov, S. I.; Loscha, K.; Kokoreva, O. V.; Yufit, D. S.; Howard, J. A. K.; de Meijere, A. *Synlett* **2000**, *12*, 1741–1744.




Figure 4. MALDI-TOF analysis of GST-LSD1 incubated with *cis*- or *trans*-3-chloroallyl-Lys-4 H3-21 (**3** and **4**). (A) Inactivator **3** is seen as a minor peak, while a new signal corresponding to the predicted mass of a **3**-FAD adduct is now apparent. Additionally, a signal corresponding to the hydrolysis of **3**, forming H3-21 is noted. Possible intramolecular cyclization of the activated peptide is seen as the major peak. (B) Inactivator **4** is seen as a minor peak, while a new signal corresponding to the predicted mass of a **4**-FAD adduct is now apparent. A signal corresponding to the hydrolysis of **4**, forming H3-21, is noted. Possible intramolecular cyclization of the activated peptide is seen as the major peak.

Perbenzylation of commercially available L-Glu (**11**), selective reduction of the side chain ester to the alcohol (**12**), and Swern oxidation yields the amino aldehyde **13** in an overall 43% yield (Scheme 4).²⁸ Horner–Wadsworth–Emmons reaction of the aldehyde **13** with *t*-butyl diethylphosphonoacetate provides the α,β -unsaturated ester **14**²⁹ for cyclopropanation with diazomethane yielding **15**.³⁰ The α,β -cyclopropyl *t*-butyl ester **15** can be selectively hydrolyzed under acidic conditions allowing the acid **16** to undergo Curtius rearrangement to yield the *tert*-butyl carbamate protected cyclopropylamine **17**.³¹ Removal of the benzyl esters can be accomplished under hydrogenation conditions in a Parr shaker to provide the deprotected α -amino acid. Treatment with Fmoc-OSu yields Fmoc-*endo*-cyclopropyl-Lys(Boc)-OH (**9**). TFA treatment of **9** allows for the incorporation of two methyl groups by reductive amination, yielding Fmoc-*endo*-dimethylcyclopropyl-Lys-OH (**10**) (Scheme 5).³²



(28) Kokotos, G.; Padron, J. M.; Martin, T.; Gibbons, W. A.; Martin, V. S. *J. Org. Chem.* **1998**, *63*, 3741–3744.

(29) Barrett, A. G. M.; Head, J.; Smith, M. L.; Stock, N. S.; White, A. J. P.; Williams, D. J. *J. Org. Chem.* **1999**, *64*, 6005–6018.

(30) Tchilibon, S.; Kim, S. K.; Gao, Z. G.; Harris, B. A.; Blaustein, J. B.; Gross, A. S.; Duong, H. T.; Melman, N.; Jacobson, K. A. *Bioorg. Med. Chem.* **2004**, *12*, 2021–2034.

(31) Raju, B.; Anandan, S.; Gu, S.; Herradura, P.; O'Dowd, H.; Kim, B.; Gomez, M.; Hackbarth, C.; Wu, C.; Wang, W.; Yuan, Z.; White, R.; Trias, J.; Patel, D. V. *Bioorg. Med. Chem. Lett.* **2004**, *14*, 3103–3107.

(32) Arvidsson, L. E.; Johansson, A. M.; Hacksell, U.; Nilsson, J. L. G.; Svensson, K.; Hjorth, S.; Magnusson, T.; Carlsson, A.; Lindberg, P.; Andersson, B.; Sanchez, D.; Wikstrom, H.; Sundell, S. *J. Med. Chem.* **1988**, *31*, 92–99.

Scheme 4. Synthesis of the Amino Aldehyde (S)-Benzyl 2-(dibenzylamino)-5-oxopentanoate (**13**)**Scheme 5.** Synthesis of Fmoc-*endo*-cyclopropyl-Lys(Boc)-OH (**9**) and Fmoc-*endo*-dimethylcyclopropyl-Lys-OH (**10**)

Fmoc amino acids **9** and **10** were used in standard Fmoc SPPS to provide peptides **7** and **8**.²²

In contrast to the results with propargylamine and chlorovinyl derivatives, *endo*-cyclopropylamine containing peptides **7** and **8** failed to inactivate LSD1. Both peptides displayed a reversible mode of inhibition with an estimated $K_i = 6.11 \pm 0.86 \mu M$ and $24.2 \pm 2.7 \mu M$, respectively, determined by Dixon analysis assuming a competitive inhibitory model (Figure 5). Interestingly, the dimethylated peptide (**8**) displayed lower potency than the unmethylated analogue (**7**), although **8** was projected to be the better model of the dimethyl-Lys-4 substrate. This result suggests that the incorporation of the cyclopropyl moiety not only as *exo* as in peptide **6**,²² but also as *endo* effects the binding of the inhibitor peptide enough to eliminate oxidative turnover by LSD1. We suggest that the radical/cation stabilizing function of the benzyl group, lacking in **7** and **8**, plays a key effector function in the tranlycypromine inactivation mechanism of LSD1.

Hydrazino Analogues as LSD1 Inhibitors. As mentioned, phenelzine was previously shown to be a weak inhibitor of LSD1, suggested to be 20-fold weaker than tranlycypromine.¹⁴ To analyze this further, we embarked on the synthesis of hydrazine analogue **18**. This was readily achieved by displacement of the mesylate functionality with hydrazine akin to generation of inactivators **3** and **4** (Scheme 2).²¹ Initial enzymatic inhibition studies revealed compound **18** to be a highly potent time-dependent inhibitor of LSD1. Limited sensitivity of the 4-aminoantipyrine and 3,5-dichloro-2-hydroxybenzenesulfonic acid coupled assay²¹ prevented a precise determination of the inhibitory parameters. We therefore utilized a more sensitive Amplex Red³³ coupled assay for the detection of H_2O_2 produced during enzymatic turnover of substrate. We determined that hydrazine analogue **18** had a $K_{i(inact)}$ and $k_{(inact)}$

(33) Zhou, M.; Diwu, Z.; Panchuk-Voloshina, N.; Haugland, R. P. *Anal. Biochem.* **1997**, *253*, 162–168.




Figure 5. Inhibition of GST-LSD1 by *endo*-cyclopropyl-Lys-4 H3-21 (**7**) and *endo*-dimethylcyclopropyl-Lys-4 H3-21 (**8**). (A and C) Steady-state progress curves obtained for the inhibition of LSD1 in the presence of concentrations of **7** ranging from 0 to 49.6 μM and concentrations of **8** ranging from 0 to 720 μM . (B and D) Steady-state velocities obtained in (A) and (C) were used to determine the K_i for compounds **7** and **8** by Dixon analysis.




Figure 6. Time- and concentration-dependent inactivation of GST-LSD1 by hydrazino-Lys-4 H3-21 (**18**). (A) Steady-state progress curves obtained for the inactivation of LSD1 in the presence of concentrations of **18** ranging from 0.1 to 0.4 μM . (B) Rate constants (k_{obs}) for the time-dependent inactivation of LSD1 by **18** were extracted from the steady-state data in (A) by single exponential fits and analyzed by the method of Kitz and Wilson to determine k_{inact} and $K_{i(\text{inact})}$ values.

of $4.35 \pm 0.86 \text{ nM}$ and $0.247 \pm 0.018 \text{ min}^{-1}$, respectively (Figure 6). This makes hydrazino-Lys-4 H3-21 (**18**) approximately 25-fold more potent than **2**, the previous best in class LSD1 inactivator which contains the *N*-methylpropargylamine motif (Table 1). The significantly lower $K_{i(\text{inact})}$ of **18** compared with that of **1** and **2** was unexpected and may reflect a higher affinity for the encounter complex between **18** and LSD1. If so, this may suggest that the lower $\text{p}K_a$ of the hydrazine

versus the amino functionality contributes to enhanced affinity, and that the neutral rather than the positively charged species preferentially binds to LSD1. Alternatively, the $K_{i(\text{inact})}$ of **18** may not correspond to its K_d but instead may be composed of a series of complex rate constants.

Spectroscopic analysis of **18** inactivated LSD1 showed loss of the visible maxima, consistent with flavin modification (Figure 7A). The MALDI mass spectrum of the inactivated mixture revealed a peak with $m/z = 3024$, consistent with the formation of a peptide-FAD adduct with concurrent loss of N_2 (Figure 7B). In accordance with prior proposals for phenelzine inactivation of MAO, we suggest an LSD1 inactivation mechanism that initially involves a two electron oxidation to form the corresponding diazene (Scheme 6, path a). We propose that after reoxidation of the FAD by molecular oxygen, a two electron oxidation of the diazene yields the diazonium species, an excellent leaving group. Attack from the N^5 of the reduced flavin leads to the inactivator-FAD adduct with loss of N_2 (Scheme 6 path b).^{34,35} Interestingly, the mass spectrum also shows evidence of two peptide degradation pathways. The first correlates to an aldehyde containing peptide at $m/z = 2253$. This product could potentially stem from nonenzymatic hydrolysis of a hydrazone that can be produced during the initial oxidation of the inhibitor to the diazene (Scheme 6, path d). A second degradation correlates to the loss of N_2H_2 from the oxidatively activated diazene peptide ($m/z = 2237$). This could potentially be produced through the abstraction of the beta proton and loss of N_2 yielding an olefin (Scheme 6, path c), or through an internal cyclization of the peptide as similarly proposed previously in the case of the chlorovinyl inactivators (Scheme 3). Quantification of the relative product ratios in the LSD1 reaction with **18** is difficult because of the challenge of separating and detecting these chemical species by HPLC. We cannot also not rule out the possibility that the LSD1 inactivation mechanism related to **18** also involves some covalent enzyme modification reactions.

(34) Clineschmidt, B. V.; Horita, A. *Biochem. Pharmacol.* **1969**, *18*, 1011–1020.

(35) Yu, P. H.; Tipton, K. F. *Biochem. Pharmacol.* **1989**, *38*, 4245–4251.




Figure 7. Spectroscopic and MALDI-TOF analysis of hydrazino-Lys-4 H3-21 (**18**) treated GST-LSD1. (A) UV/vis spectra of native LSD1 (blue) shows the distinctive two maxima of the fully oxidized flavin and the one electron reduced semiquinone. LSD1 treated with **18** (red) leads to the bleaching of the flavin spectra with no new maximum recorded. (B) In the MALDI-TOF analysis, **18** is seen as a minor peak, while a major peak corresponding to the predicted mass of an **18**-FAD adduct is now evident. Additionally, a signal corresponding to the hydrolysis of **18**, forming the aldehyde containing peptide is noted along with a possible degradation to the olefin or intramolecular cyclization.

The impressive inhibitory characteristics with hydrazino-Lys-4 H3-21 (**18**) led us to reinvestigate the inhibitory characteristics of phenelzine for LSD1. Remarkably, we found that phenelzine showed a $K_{i(\text{inact})}$ of $17.6 \pm 2.8 \mu\text{M}$ and a $k_{i(\text{inact})}$ of $0.955 \pm 0.085 \text{ min}^{-1}$ (Figure 8). To rule out that the perceived LSD1 inhibition was somehow related to the interfering action of phenelzine on peroxide detection, we performed the following additional experiments. We demonstrated that inactivation of LSD1 was greater when pretreated with phenelzine, in the absence of horseradish peroxidase, followed by assay (Figure 9A). We showed that additional horseradish peroxidase failed to relieve the LSD1 inhibition (Figure 9B). Finally, we determined in a direct assay using mass spectrometry that phenelzine-treated LSD1 was unable to induce loss of a methyl group from an H3-21 dimethyl-Lys substrate peptide (Figure 10). While considerably less potent than hydrazino-Lys-4 H3-21 (**18**), phenelzine is approximately 35-fold more efficient as an LSD1 inactivator than tranlycypromine in our hands, and appears to be comparable to a newly described class of tranlycypromine analogues.³⁶ The inactivation efficiency of phenelzine toward LSD1 appears comparable to, if not greater than, its inhibitory effect versus MAOs.³⁷ Although we cannot account for the inhibitory differences regarding tranlycypromine and phenelzine between our work and a prior study,¹⁴ we note

that the assay methods were quite distinct. Moreover, the tranlycypromine LSD1 inhibition parameters measured previously by us²⁰ were in close agreement with those of Schmidt and McCafferty.¹⁹

Given the relative in vitro inhibitory potency of phenelzine toward recombinant LSD1, we considered that phenelzine might also block LSD1 in live cells. To examine the effects of phenelzine as a demethylase inhibitor in cells, we explored the effects of phenelzine on a thyroid hormone (T3) inhibited TSH α luciferase reporter transfected in cells.³⁸ As shown, LSD1 inhibition increases luciferase activity both in the absence and presence of T3 but maintains negative regulation by T3 (Figure 11). Assessment of the methylation status of Lys-4 of histone H3 by ChIP (chromatin immunoprecipitation) in response to phenelzine, revealed that mono and dimethylation of the TSH α reporter region was enhanced by phenelzine, whereas the trimethylation level was unaffected (Figure 12). These findings suggest that mono- and dimethylation of Lys-4 H3 may enhance basal transcription of TSH α promoter in the absence or presence of T3. These results correlate with that expected for LSD1 inhibition (as opposed to a trimethyl-Lys demethylase) and establish the pharmacologic value of phenelzine as an epigenetic probe.

Summary

In this study, we have designed, synthesized, and examined several novel H3 tail peptide analogues containing classical monoamine oxidase warhead groups as LSD1 inhibitors. The chlorovinyl-containing inhibitors are comparable in potency to alkynyl inhibitors described previously, whereas the hydrazine containing H3 peptide is the most potent suicide inactivator known for LSD1. Consistent with this finding, the hydrazine containing MAO inhibitor phenelzine is the most potent small molecule LSD1 inhibitor that has emerged from our studies. Its potency is such that the pharmacology of phenelzine, which is clearly active against MAOs, is likely enhancing Lys-4 H3 methylation in its therapeutically useful range. It could for example synergize with HDAC and DNA methyltransferase inhibitors to induce the re-expression of silenced tumor suppressor genes.^{39,40}

In contrast to the peptide and small molecule hydrazines, there is discordance in inactivation potential of propargyl and cyclopropyl inhibitors of LSD1. Whereas propargylamine peptide inhibitors are efficient LSD1 inhibitors, peptide cyclopropyl compounds are not. This contrasts with the pargyline and tranlycypromine effects on LSD1. Taken together, these studies reveal a complex mosaic in molecular recognition among LSD1, its substrates, and inhibitory compounds.

Experimental Section

General. All synthetic reactions were carried out under an inert argon atmosphere using standard techniques. Solvents were purchased from Aldrich as anhydrous and used as is. NMR spectra were recorded on a Varian 400 MHz spectrometer. MALDI-TOF spectra were recorded on a Applied Biosystems Voyager DE-STR mass spectrometer. ESI-TOF spectra were recorded on an Applied Biosystems Sciex instrument.

cis-3-Chloroallyl-Lys-4 H3-21 (3). Lyophilized mesyl-Lys-4 H3-21 (**5**) (5.0 mg, 2.1 μmol) was dissolved in 500 μL of 1:1 H₂O/


(36) Ueda, R.; Suzuki, T.; Mino, K.; Tsumoto, H.; Nakagawa, H.; Hasegawa, M.; Sasaki, R.; Mizukami, T.; Miyata, N. *J. Am. Chem. Soc.* **2009**, *131*, 17536–17537.

(37) Patek, D. R.; Hellerman, L. *J. Biol. Chem.* **1974**, *249*, 2373–2380.

(38) Wang, D.; Xia, X.; Liu, Y.; Oetting, A.; Walker, R. L.; Zhu, Y.; Meltzer, P.; Cole, P. A.; Shi, Y. B.; Yen, P. M. *Mol. Endocrinol.* **2009**, *23*, 600–609.

(39) Jones, P. A.; Baylin, S. B. *Cell* **2007**, *128*, 683–692.

(40) Minucci, S.; Pelicci, P. G. *Nat. Rev. Cancer* **2006**, *6*, 38–51.

Scheme 6. Proposed Mechanism of Inactivation of GST-LSD1 by Hydrazino-Lys-4 H3-21 (**18**)^a

^a Pathway (a), two electron oxidation of **18** by the flavin yields the diazene. A second oxidation to the primary diazonium species produces a powerful electrophilic site at the alpha carbon. Pathway (b), nucleophilic attack by the flavin N^5 yields inactivated LSD1 as an **18-FAD** adduct. Pathway (c), abstraction of the beta proton leads to the olefin through loss of N_2 . Pathway (d), the competing oxidation leads to the formation of the hydrazone which can non-enzymatically hydrolyze to the aldehyde containing peptide oxo-Lys-4 H3-21.




Figure 8. Time- and concentration-dependent inactivation of GST-LSD1 by the small molecule MAO inactivator phenelzine. (A) Steady-state progress curves obtained for the inactivation of LSD1 in the presence of concentrations of phenelzine ranging from 15.6 to 250 μM . (B) Rate constants (k_{obs}) for the time-dependent inactivation of LSD1 by phenelzine were extracted from the steady-state data in A by single exponential fits and analyzed by the method of Kitz and Wilson to determine k_{inact} and $K_{i(\text{inact})}$ values.




Figure 9. GST-LSD1 inactivation by phenelzine. (A) LSD1 inactivation is more pronounced when preincubated with phenelzine. (B) LSD1 inactivation is independent of the horseradish peroxidase enzyme concentration.

CH_3CN . *cis*-3-Chloroallylamine hydrochloride (82 mg, 640 μmol) in 500 μL of 1:1 $\text{H}_2\text{O}/\text{CH}_3\text{CN}$ was added to the solution followed by freshly distilled triethylamine (120 μL , 860 μmol). The reaction rotated 70 h at 25 $^\circ\text{C}$. The crude reaction mixture was diluted to 15 mL with H_2O , acidified to pH 2 with TFA, and lyophilized to an oil. The oil was diluted to 3 mL with H_2O and injected onto a




Figure 10. MALDI-TOF assay demonstrating the inactivation of GST-LSD1 by phenelzine. (A) LSD1 preincubated with phenelzine prior to exposure to dimethyl-Lys-4 H3-21 substrate fails to appreciably demethylate. (B) LSD1 efficiently demethylates dimethyl-Lys-4 H3-21 substrate yielding monomethyl Lys-4 H3-21 and Lys-4 H3-21.

prep scale column for RP-HPLC purification. Analysis by MALDI-TOF showed an expected/observed $m/z = 2328.31$.

trans-3-Chloroallyl-Lys-4 H3-21 (4). Lyophilized mesyl-Lys-4 H3-21 (**5**) (5.0 mg, 2.1 μmol) was dissolved in 500 μL of 1:1 $\text{H}_2\text{O}/\text{CH}_3\text{CN}$. *trans*-3-chloroallylamine hydrochloride (82 mg, 640 μmol) in 500 μL of 1:1 $\text{H}_2\text{O}/\text{CH}_3\text{CN}$ was added to the solution followed by freshly distilled triethylamine (120 μL , 860 μmol). The reaction rotated 70 h at 25 $^\circ\text{C}$. The crude reaction mixture was diluted to 25 mL with H_2O , acidified to pH 2 with TFA, and lyophilized to an oil. The oil was diluted to 3 mL with H_2O and injected onto a prep scale column for RP-HPLC purification. Analysis by MALDI-TOF showed an expected/observed $m/z = 2328.31$.

Mesyl-Lys-4 H3-21 (5). The primary alcohol of resin bound peptide was treated with 20 equivalents of mesyl chloride in the presence of 40 equivalents of triethylamine in tetrahydrofuran for 20 h at room temperature. Universal deprotection and cleavage of the peptide from the Wang resin, in the presence of the mesylate, was accomplished by treating the resin bound peptide with Reagent K (95:5 trifluoroacetic acid/ H_2O in the presence of phenol, ethanedithiol, and thioanisole) for 4 h at room temperature. Precipitation of the peptide with diethyl ether followed by lyophilization yielded crude peptide as an off-white solid that was purified by prep scale RP-HPLC. Analysis by MALDI-TOF showed an expected/observed $m/z = 2333.28$.

endo-Cyclopropyl-Lys-4 H3-21 (7). Standard Fmoc solid phase peptide synthesis technique was utilized to assemble the *endo*-cyclopropyl-Lys-4 H3-21 peptide. The *endo*-cyclopropyl-Lys-4 residue was inserted as the Fmoc monomer **9**. Universal deprotection and cleavage of the peptide from the Wang resin was accomplished with Reagent K (95:5 trifluoroacetic acid: H_2O in the presence of phenol, ethanedithiol, and thioanisole) for 5 h at 25 $^\circ\text{C}$. Precipitation of the peptide with diethyl ether followed by lyophilization yielded crude peptide as an off-white solid that was purified by prep scale RP-HPLC. Analysis by MALDI-TOF showed an expected/observed $m/z = 2266.31$.

endo-Dimethylcyclopropyl-Lys-4 H3-21 (8). Standard Fmoc solid phase peptide synthesis technique was utilized to assemble




Figure 11. T_3 and phenelzine effects on TSH α promoter activity and Lys-4 H3 methylation. α -23 cells were treated 24 h with no hormone/phenelzine (control), 0.1 μM T_3 , 10 μM phenelzine, or both. The cell lysates were prepared and luciferase activities were measured as described in Experimental Section. Shown are the mean of triplicate samples \pm SD normalized to control as 100%. Similar findings were found in two other experiments. Data were analyzed by ANOVA and * = $p < 0.05$ and ** = $p < 0.01$ difference between indicated samples and EtOH control samples.




Figure 12. T_3 and phenelzine regulation of methylation of Lys-4 H3. ChIP assay was performed as described in the Experimental section using antibodies against mono-, di- and trimethylated H3K4. Similar findings were observed in two other experiments. The Y axis shows relative H3K4 methylation based upon changes in cycle threshold number above background after each treatment. Data were analyzed by ANOVA and * = $p < 0.05$ difference between indicated samples and EtOH control samples.

the *endo*-dimethylcyclopropyl-Lys-4 H3-21 peptide. The *endo*-dimethylcyclopropyl-Lys-4 residue was inserted as the Fmoc monomer **10**. Universal deprotection and cleavage of the peptide from the Wang resin was accomplished with Reagent K (95:5 trifluoroacetic acid/ H_2O in the presence of phenol, ethanedithiol, and thioanisole) for 5 h at 25 $^\circ\text{C}$. Precipitation of the peptide with

diethyl ether followed by lyophilization yielded crude peptide as an off-white solid that was purified by prep scale RP-HPLC. Analysis by MALDI-TOF showed an expected/observed m/z = 2294.35.

Fmoc-endo-cyclopropyl-Lys(Boc)-OH (9). The benzylated amino acid **17** (600 mg, 1.1 mmol) in 10 mL of absolute ethanol had 100 mg of palladium on carbon (10 wt % wet) added to it and the suspension degassed with argon. Hydrogenation, using a Parr shaker apparatus, was performed for 15 h under 55 psi of hydrogen gas. Following the hydrogenation, 10 mL of H₂O was added to the suspension to dissolve the free amino acid. The suspension was filtered through a plug of Celite and washed with H₂O and ethanol. The solvent was removed *in vacuo* to yield a white solid which was then suspended in 10 mL of 1:1 H₂O/Acetone. Potassium carbonate (684 mg, 4.95 mmol) and Fmoc-succinimidyl carbonate (668 mg, 1.98 mmol) were added and the reaction was stirred at 25 °C for 15 h. The reaction was concentrated *in vacuo* to an off-white solid and purified by RP-HPLC on a prep scale column using a H₂O/Acetonitrile gradient with 0.05% formic acid to yield 106 mg (20%) of **9** as a white powder following lyophilization. ¹H (CD₃Cl₃, 400 MHz): δ 7.75 (d, J = 7.2 Hz, 2H); 7.58 (d, J = 7.2 Hz, 1H); 7.38 (t, J = 7.2 Hz, 2H); 7.29 (t, J = 7.2 Hz, 2H); 5.67 (d, 1H); 4.95 (d, 1H); 4.67 (m, 1H); 4.37 (t, 2H); 4.21 (d, 1H); 2.46 (m, 1H); 2.20 (m, 1H); 2.06 (m, 1H); 1.79 (m, 2H); 0.94 (m, 1H); 0.62 (m, 1H); 0.48 (m, 1H). HRMS: expected: 481.23 [M+H], observed: 503.2125 [M + Na].

Fmoc-endo-dimethylcyclopropyl-Lys-OH · TFA (10).³² Fmoc amino acid **9** (40 mg, 0.083 mmol) in 1 mL of dichloromethane was cooled to 0 °C while stirring. One mL of trifluoroacetic acid was added and stirred for 15 min before being allowed to warm to 25 °C over 45 min. The reaction was concentrated *in vacuo* to an oil and residual solvent was removed by high vacuum over 2 h. The amine was dissolved in 1.5 mL of acetonitrile followed by the addition of formaldehyde (37% w/w Aq, 12.5 mg, 0.415 mmol). Sodium cyanoborohydride (15.6 mg, 0.249 mmol) was added as one portion and stirred 5 min. Glacial acetic acid was added dropwise to keep the pH 4–5. The reaction stirred 15 h before being concentrated *in vacuo* to an oil and purified by RP-HPLC on a prep scale column using a H₂O: Acetonitrile gradient with 0.05% trifluoroacetic acid to yield 30 mg (70%) of **10** as a white powder following lyophilization. ¹H (CD₃Cl₃, 400 MHz): δ 7.72 (d, 2H); 7.55 (t, 2H); 7.35 (t, 2H); 7.26 (t, 2H); 5.93 (d, 1H); 4.40 (m, 1H); 4.30 (d, 2H); 4.14 (t, 1H); 2.79 (bs, 6H); 2.29 (m, 1H); 2.00 (m, 1H); 1.80 (m, 1H); 1.50 (m, 2H); 1.22 (m, 2H); 0.68 (m, 1H). HRMS: expected: 409.20, observed: 409.2118 [M + H].

(S)-Dibenzyl 2-(dibenzylamino)pentanedioate (11).²⁸ Glutamic acid (12.4 g, 84.2 mmol), potassium carbonate (46.5 g, 337 mmol), and potassium hydroxide (9.5 g, 168 mmol) in 125 mL of H₂O was brought to reflux while stirring. Benzyl bromide (50.0 mL, 421 mmol) was added dropwise over 30 min and allowed to reflux an additional 30 min. The cooled reaction was extracted with diethyl ether 3 × 75 mL. The pooled organics were washed with saturated brine 2 × 50 mL. The organic phase was washed 2 × 75 mL with brine and dried over MgSO₄, filtered, and concentrated *in vacuo* to an oil. The crude product was purified by silica gel column chromatography in hexane/ethyl acetate (99:1–80:20) to yield 17 g (56%) of **11** as a clear viscous oil. ¹H (CD₃Cl₃, 400 MHz): δ 7.41–7.19 (m, 20H); 5.21 (q, J = 30.4 and 12.4 Hz, 2H); 4.98 (q, J = 12.4 and 5.2 Hz, 2H); 3.88 (d, J = 14 Hz, 2H); 3.49 (d, J = 14 Hz, 2H); 3.41 (t, J = 7.6 Hz, 1H); 2.51 (m, 1H); 2.35 (m, 1H); 2.06 (q, J = 7.2 Hz, 2H).

(S)-Benzyl 2-(dibenzylamino)-5-hydroxypentanoate (12).²⁸ The benzyl protected amino acid **11** (19 g, 37.4 mmol) in 200 mL of anhydrous tetrahydrofuran was cooled to –10 °C with an ice/acetone bath while stirring under an argon atmosphere. DIBAL (1 M in toluene, 112 mL, 112 mmol) was added dropwise over 40 min. Following the addition, the reaction was warmed to 0 °C with an ice water bath and stirred 100 min. The reaction was quenched by the addition of 80 mL of H₂O and stirred an addition 20 min

before being filtered through a pad of Celite. The filtrate was dried over MgSO₄, filtered, and concentrated *in vacuo* to an oil. The crude product was purified by silica gel column chromatography in petroleum ether/diethyl ether (90:10–50:50) to yield 12 g (80%) of **12** as a clear viscous oil. ¹H (CD₃Cl₃, 400 MHz): δ 7.45–7.21 (m, 15H); 5.21 (q, J = 31.5 and 12 Hz, 2H); 3.91 (d, J = 14 Hz, 2H); 3.51 (d, J = 14 Hz, 2H); 3.48 (q, J = 5.8 Hz, 2H); 3.38 (t, J = 7.6 Hz, 1H); 1.81 (m, 2H); 1.71 (m, 2H) 1.48 (m, 2H).

(S)-Benzyl 2-(dibenzylamino)-5-oxopentanoate (13).²⁸ Oxalyl chloride (2.25 mL, 25.8 mmol) in 140 mL anhydrous dichloromethane at –78 °C had DMSO (3.65 mL, 51.5 mmol) added dropwise and stirred 25 min under an argon atmosphere. Alcohol **12** (5.2 g, 12.9 mmol) in 50 mL of anhydrous dichloromethane was added dropwise to this solution and stirred an additional 30 min. Triethylamine (8.6 mL, 61.8 mmol) was added to the reaction and stirred 30 min at –78 °C, triethylamine (8.6 mL, 61.8 mmol) was again added to the reaction and allowed to warm to 0 °C over 30 min. 100 mL of H₂O was added to quench the reaction while warming to 25 °C. The organic phase was separated and the aqueous phase was extracted 2 × 100 mL with dichloromethane. The pooled organics were washed 1 × 75 mL with saturated sodium bicarbonate and saturated brine, dried over MgSO₄, filtered, and concentrated *in vacuo* to a golden oil. Residual solvent was removed by high vacuum over 2 h. The product aldehyde was used without further purification yielding 5.0 g (97%) of **13** as an oil. ¹H (CD₃Cl₃, 400 MHz): δ 9.59 (s, 1H); 7.43–7.23 (m, 15H); 5.23 (q, J = 27.6 and 12 Hz, 2H); 3.87 (d, J = 13.6 Hz, 2H); 3.50 (d, J = 13.6 Hz, 2H); 3.35 (t, J = 7.8 Hz, 1H); 2.53 (m, 1H); 2.42 (m, 1H); 2.03 (m, 2H); 1.55 (m, 2H).

(S,E)-7-Benzyl 1-tert-butyl 6-(dibenzylamino)hept-2-enedioate (14).²⁹ *tert*-butyl diethylphosphonoacetate (4.4 mL, 18.7 mmol) was added dropwise to a stirring suspension of sodium hydride (60% dispersion in oil, 717 mg, 18.7 mmol) in 50 mL of anhydrous tetrahydrofuran at 0 °C under an argon atmosphere. The reaction is allowed to warm to 25 °C over 30 min before being cooled to –10 °C with an ice/acetone bath. Aldehyde **13** (5.0 g, 12.5 mmol) in 50 mL of anhydrous tetrahydrofuran was added dropwise to the solution and stirred 30 min. After the solvent was removed *in vacuo*, the oil was partitioned in 100 mL of H₂O and diethyl ether. The aqueous phase was extracted 1 × 50 mL with diethyl ether. The pooled organics were washed 1 × 50 mL with saturated sodium bicarbonate and saturated brine, dried over MgSO₄, filtered, and concentrated *in vacuo* to a golden oil. The crude product was purified by silica gel column chromatography in petroleum ether/diethyl ether (99:1–90:10) to yield 5.3 g (85%) of **14** as a slightly yellow oil. ¹H (CD₃Cl₃, 400 MHz): δ 7.44–7.20 (m, 15H); 6.70 (dt, J = 15.2 and 6.8 Hz, 1H); 5.58 (dt, J = 15.2 and 1.2 Hz); 5.21 (q, J = 28.7 and 12 Hz, 2H); 3.88 (d, J = 14 Hz, 2H); 3.50 (d, J = 14 Hz, 2H); 3.34 (t, J = 7.6 Hz, 1H); 2.32 (m, 1H); 2.05 (m, 1H); 1.86 (m, 2H); 1.46 (s, 9H). HRMS: expected: 500.27 [M+H], observed: 500.2799 [M+H].

tert-Butyl 2-((S)-4-(benzyloxy)-3-(dibenzylamino)-4-oxobutyl)cyclopropane carboxylate (15).³⁰ Unsaturated *tert*-butyl ester **14** (5.25 g, 10.5 mmol) in 2:1 anhydrous dichloromethane/anhydrous diethyl ether was cooled to 0 °C while stirring under an argon atmosphere. Palladium(II) acetate (17.7 mg, 0.079 mmol) was added as one portion and stirred 5 min. Diazomethane (estimated at 0.37 M in diethyl ether, 100 mL, 37 mmol) (see below for diazomethane generation procedure) was added dropwise over 35 min via liquid addition funnel. The reaction was allowed to warm to 25 °C while stirring overnight. The reaction was filtered through a plug of Celite and concentrated *in vacuo* to a golden oil. Residual solvent was removed by high vacuum over 3 h. The cyclopropyl *tert*-butyl ester was used without further purification yielding 5.3 g (98%) of **15** as an oil. ¹H (CD₃Cl₃, 400 MHz): 2 predominant rotamers present δ 7.42–7.20 (m, 15H); 5.20 (q, J = 33.2 and 12 Hz, 2H); 3.89 (d, J = 14 Hz, 2H); 3.50 (d, J = 14 Hz, 2H); 3.35 (t, J = 7.6 Hz, 1H); 1.83 (m, 2H); 1.42 (s, 9H); 1.29 (m, 1H); 1.17

(m, 2H); 1.12 (m, 1H); 0.96 (m, 1H); 0.47 (m, 1H). HRMS: expected 514.29 [M + H], observed 514.2955 [M + H].

Diazomethane. Diazomethane was generated according to Aldrich technical bulletin AL-180 in an Aldrich mini diazald apparatus. Diazald (5.0 g, 23 mmol) in 45 mL of diethyl ether was added dropwise over 20 min to a 65 °C stirring solution of potassium hydroxide (2.5 g, 44.6 mmol) in 4 mL of H₂O, 8 mL of diethyl ether, and 14 mL of 2-(2-ethoxyethoxy)ethanol. The intensely yellow-colored distillate is collected and stored at -78 °C in a brown bottle and used within 2 h.

2-((S)-4-(Benzyloxy)-3-(dibenzylamino)-4-oxobutyl)-cyclopropanecarboxylic acid (16). Cyclopropyl *tert*-butyl ester **15** (5.3 g, 10.3 mmol) in 100 mL of dichloromethane was cooled to 0 °C while stirring. 100 mL of trifluoroacetic acid was added and stirred for 15 min before being allowed to warm to 25 °C over 45 min. The solvent was removed *in vacuo*, and the oil partitioned in 100 mL of H₂O and dichloromethane. The aqueous phase was extracted 2 × 25 mL with dichloromethane. The pooled organics were washed 1 × 50 mL with saturated brine, dried over MgSO₄, filtered, and concentrated *in vacuo* to an oil. Residual solvent was removed by high vacuum over 2 h. The carboxylic acid was used without further purification yielding 4.7 g (99%) of **16** as an oil. ¹H (CD₃Cl₃, 400 MHz): δ 7.43–7.20 (m, 15H); 5.21 (q, *J* = 28.4 and 12 Hz, 2H); 3.90 (d, *J* = 14 Hz, 2H); 3.54 (d, *J* = 14 Hz, 2H); 3.36 (t, *J* = 7.2 Hz, 1H); 1.84 (m, 2H); 1.43 (m, 1H); 1.32 (m, 1H); 1.25 (m, 2H); 1.10 (m, 1H); 0.62 (m, 1H). HRMS: expected 458.23 [M + H], observed 458.2326 [M + H].

(2S)-Benzyl 4-(2-(*tert*-butoxycarbonylamino)cyclopropyl)-2-(dibenzylamino) butanoate (17).³¹ Acid **16** (4.7 g, 10.3 mmol) in 100 mL of anhydrous toluene was cooled to 0 °C while stirring under an argon atmosphere. Triethylamine (4.25 mL, 30.9 mmol) and diphenylphosphorylazide (4.54 mL, 21.0 mmol) were added and the reaction warmed to 25 °C over 3 h. The reaction was washed 3 × 50 mL with H₂O, 1 × 25 mL with saturated brine, dried over MgSO₄, filtered, and concentrated *in vacuo*. Residual solvent was removed by high vacuum over 4 h. The azide was dissolved in 100 mL of anhydrous *tert*-butanol while stirring under an argon atmosphere and heated to reflux for 18 h. The reaction was cooled to 25 °C and concentrated *in vacuo* to a golden oil. The oil was partitioned between 100 mL of H₂O and dichloromethane. The organic phase was washed 1 × 25 mL with saturated sodium bicarbonate and saturated brine, dried over MgSO₄, filtered, and concentrated *in vacuo*. The crude product was purified by silica gel column chromatography in petroleum ether: diethyl ether (95:5–60:40) to yield 3.6 g (66%) of **17** as a clear oil. ¹H (CD₃Cl₃, 400 MHz): δ 7.44–7.20 (m, 15H); 5.21 (q, *J* = 32.8 and 12 Hz, 2H); 3.89 (d, *J* = 14 Hz, 2H); 3.49 (d, *J* = 14 Hz, 2H); 3.38 (t, *J* = 7.6 Hz, 1H); 2.13 (m, 1H); 1.84 (m, 2H); 1.44 (s, 9H); 1.38 (m, 1H); 1.18 (m, 1H); 0.55 (m, 1H); 0.49 (m, 1H); 0.37 (m, 1H). HRMS: expected 529.30 [M + H], observed 529.3064 [M + H].

Hydrazino-Lys-4 H3-21 (18). Lyophilized mesyl-Lys-4 H3-21 (**5**) (5.0 mg, 2.1 μmol) was dissolved in 750 μL of 1:1 H₂O/CH₃CN. Hydrazine monohydrate (57 μL, 860 μmol) was added to the solution and rotated 70 h at 25 °C. The crude reaction mixture was diluted to 3 mL with H₂O, acidified to pH 2 with TFA, and injected onto a prep scale column for RP-HPLC purification. Analysis by MALDI-TOF showed an expected/observed *m/z* = 2269.33.

Enzyme Expression and Purification. LSD1 (aa 171–852) subcloned into the pGEX-6P-1 vector (GE Healthcare) was over-expressed in *E. coli* BL21-CodonPlus(DE3)-RIPL cells (Stratagene).²² Cells were grown to an OD_{600 nm} of 1.8 in CircleGrow Media (Q-Biogene) at 37 °C then induced with 1 mM final IPTG and grown for 20 h at 16 °C. Cell pellets were harvested by centrifugation at 5000 × *g* for 15 min and resuspended in ice cold lysis buffer (280 mM NaCl, 5.4 mM KCl, 20 mM Na₂HPO₄, 3.6 mM KH₂PO₄, 1 mM EDTA, 10 mM DTT, 10% glycerol, pH 7.4). The cells were then lysed via double pass on a French press (16 000–18 000 psi), and the lysates clarified by centrifugation at

25 000 × *g* for 30 min. The clarified lysate from 1 L of culture was double loaded (0.5 mL/min) onto a 5 mL glutathione sepharose 4 fast flow column (GE Healthcare) that was pre-equilibrated with lysis buffer. The column was then washed with 75 mL of lysis buffer and eluted with 5 × 5 mL fractions of lysis buffer containing 50 mM reduced glutathione (Sigma). GST-LSD1 containing fractions were pooled and dialyzed against 3 × 1 L changes of lysis buffer containing 1 mM β-mercaptoethanol instead of 10 mM DTT. The dialyzed protein was concentrated to 1–2 mL and further purified by size exclusion chromatography using sephacryl S100 high resolution media (GE Healthcare, 1.5 × 90 cm column). The protein was eluted with lysis buffer containing 1 mM β-mercaptoethanol instead of 10 mM DTT at a flow rate of 0.25 mL/min. GST-LSD1 containing fractions were pooled, concentrated, aliquoted, and stored at -80 °C. Final protein concentration was determined by Bradford assay using BSA as the standard. Purification of GST-LSD1 by this procedure yielded approximately 1 mg of protein (>90% pure) per 1 L of culture.

LSD1 Activity Assays. Initial velocity measurements were performed using a peroxidase-coupled assay, which monitors hydrogen peroxide production as previously described.²¹ The time courses of the reaction were measured under aerobic conditions using a Beckman Instruments DU series 600 spectrophotometer equipped with a thermostatted cell holder (*T* = 25 °C). The 150 μL reactions were initiated by the addition of 50 μL of buffered substrate (dimethyl-Lys-4 H3-21) solution to reaction mixtures (100 μL) consisting of 50 mM HEPES buffer (pH 7.5), 0.1 mM 4-aminoantipyrine, 1 mM 3,5-dichloro-2-hydroxybenzenesulfonic acid, 0.76 μM horseradish peroxidase (Worthington Biochemical Corporation), and 185 nM GST-LSD1. Absorbance changes were monitored at 515 nm, and an extinction coefficient of 26 000 M⁻¹ cm⁻¹ was used to calculate product formation. Under these conditions, GST-LSD1 displayed at *k*_{cat} of 4.5 ± 0.1 min⁻¹ and a *K*_m for dimethyl-Lys-4 H3-21 of 21 ± 2 μM. A secondary assay was necessary in the case of inactivator **18**. In this case, the 150 μL reactions were initiated by the addition of 50 μL of buffered substrate (dimethyl-Lys-4 H3-21) solution to reaction mixtures (100 μL) consisting of 50 mM HEPES buffer (pH 7.5), 0.1 mM Amplex Red, 0.76 μM horseradish peroxidase, and 25 nM LSD1. Absorbance changes were monitored at 571 nm, and an extinction coefficient of 52 000 M⁻¹ cm⁻¹ was used to calculate product formation. Under these conditions, our GST-LSD1 displayed at *k*_{cat} of 3.5 ± 0.2 min⁻¹ and a *K*_m for dimethyl-Lys-4 H3-21 of 20 ± 3 μM.

Inhibition Studies. Inhibitors were tested by using the peroxidase-coupled assay described above. In these experiments, assays were initiated by the addition of buffered substrate and the inhibitor simultaneously. Final substrate concentrations were 60 μM (3 × *K*_m when examining **7**), 100 μM (5 × *K*_m when examining **8**), 240 μM (12 × *K*_m when examining **3**, **4**, and phenelzine) or 600 μM (30 × *K*_m when examining **18**). With the exception of the evaluation of **18**, GST-LSD1 was present at 185 nM. Inactivator peptide **18** required a more sensitive assay and was analyzed using Amplex Red as the horseradish peroxidase cosubstrate rather than 4-aminoantipyrine and 3,5-dichloro-2-hydroxybenzenesulfonic acid as noted previously, LSD1 was present in these assays at 25 nM. Progress curves obtained in the presence of inactivators **3**, **4**, **18**, and phenelzine were fit to the following single exponential for slow-binding inhibitors which assumes a steady-state velocity of zero:⁴¹

$$\text{Product} = v_0(1 - e^{-kt})/k + \text{offset} \quad (1)$$

The *k*_{obs} values were then analyzed by the method of Kitz and Wilson to yield *k*_{inact} and *K*_{i(inact)}. The following equation was used

(41) Copeland, R. A. *Enzymes: A Practical Introduction to Structure, Mechanism, and Data Analysis*, 2nd ed.; Wiley-VCH: New York, 2000.

to extract kinetic constants from the Kitz-Wilson analysis:⁴²

$$k_{\text{obs}} = (k_{\text{inact}} * [\text{I}]) / (K_{\text{i(inact)}} + [\text{I}]) \quad (2)$$

$K_{\text{i(inact)}}$ was extrapolated to zero substrate by:

$$K_{\text{i(inact)}}^{\text{app}} = K_{\text{i(inact)}} * (1 + S/K_{\text{m}}) \quad (3)$$

The $t_{1/2}$ for inactivation at saturation was obtained by:

$$t_{1/2} = (\ln 2) / k_{\text{inact}} \quad (4)$$

Compounds **7** and **8** did not display time-dependent inhibition. Initial velocities at increasing concentrations of **7** and **8** were obtained by linear regression to reaction progress curves. These velocities were used to determine the K_{i} for **7** and **8** by Dixon analysis assuming competitive inhibition. The K_{i} was extrapolated to zero substrate by:

$$K_{\text{i}}^{\text{app}} = K_{\text{i}} * (1 + S/K_{\text{m}}) \quad (5)$$

Adduct Analysis by Absorbance Spectroscopy. GST-LSD1 (4.25 μM) was incubated with potential inactivators (30 μM), or no inhibitor in 50 mM HEPES (pH 7.5) at 25 °C. After 1 h, the samples were clarified by centrifugation at 14 000 $\times g$ for 10 min (25 °C) and the flavin absorbance spectra was recorded (350–550 nm).

MALDI-TOF Mass Spectrometric Analysis of Peptide Inactivators. Aliquots of the GST-LSD1 that was inactivated by peptides **3**, **4**, and **18** in the absorbance spectroscopic analysis above were used for MALDI-TOF mass spectrometric analysis. The sample was applied to a C₁₈ ZipTip (Millipore) column, and eluted with 75:25 CH₃CN:H₂O containing 0.05% TFA. The eluent was analyzed by MALDI-TOF mass spectrometry in α -cyano-4-hydroxycinnamic acid.

Preincubation Assay with Phenelzine. GST-LSD1 (10 μM) was incubated with phenelzine (250 μM), or no inhibitor, in 50 mM HEPES (pH 7.5) for 30 min at 25 °C. The inhibition study described above was initiated by the addition of 3 μL of preincubated LSD1 to reaction mixtures consisting of substrate and cosubstrates for a final phenelzine concentration of 5 μM in 150 μL . Two control assays were performed, the first lacking phenelzine and the second consisting of phenelzine present in the reaction mixture for 5 μM final.

MALDI-TOF Preincubation Analysis with Phenelzine. GST-LSD1 (185 nM) was incubated with phenelzine (500 μM), or no inhibitor, in 50 mM HEPES (pH 7.5) at 25 °C. After 30 min dimethyl-Lys-4 H3-21 substrate (10 μM final) was added and

incubated for 30 additional minutes. Each sample was applied to a C₁₈ ZipTip (Millipore) column, and eluted with 1:1 CH₃CN/H₂O containing 0.05% TFA. The eluent was analyzed by MALDI-TOF mass spectrometry in α -cyano-4-hydroxycinnamic acid.

Antibodies. Antibodies against mono-, di-, and trimethylated H3K4 were obtained from Abcam (Cambridge, MA).

Cell Culture, Transient Transfection, and Reporter Analyses. Monolayer cultures of clone α -23 cells derived from GH3 cells and containing a luciferase reporter construct under the control of the TSH α subunit promoter (–840 to +1),³⁸ were grown in DMEM (Life Technologies, Inc., Gaithersburg, MD) supplemented with 10% heat-inactivated fetal calf serum (Biofluids, Rockville, MD) and maintained in 5% CO₂ atmosphere at 37 °C. Cells were transfected with 300 ng DNA/well in 12-well plates with Lipofectamine 2000 (Invitrogen) according to the manufacturer's instructions. Cell culture media were changed 6 h after transfection to antibiotic-free DMEM plus 10% charcoal-dextran-treated fetal bovine serum. T₃ was added to the cells 48 h later, and cells were harvested, lysed and assayed for reporter gene activity the next day using dual luciferase assay reagents according to the manufacturer's instructions (Promega Corp., Madison, WI).

Chromatin Immunoprecipitation (ChIP) Assay. ChIP assay was performed as previously described.³⁸ α -23 cells were grown to 90% confluence in phenol red-free DMEM supplemented with 10% charcoal DEXTRAN-stripped fetal bovine serum (FBS) for 3 days. After addition of 10^{–6} M T₃ and/or 10 μM phenelzine for one hour, ChIP assays were performed according to manufacturer's protocol (Upstate Biotechnology) with some minor modifications. After treatment with T₃, chromatin was cross-linked with 1% formaldehyde in PBS, and nuclei extracted. Chromatin was sonicated to generate 500- to 1000-bp DNA fragments, and the supernatant containing precleared chromatin was incubated at 0 °C overnight with different antibodies or rabbit IgG control. After reverse cross-linking by heating the samples at 65 °C overnight, and treating with Proteinase K, DNA was purified with a QIAGEN PCR Purification Kit (QIAGEN, Chatsworth, CA) according to the manufacturer's instructions. Quantitative real-time PCR of ChIP products was performed using primers that amplified the promoter region of TSH in pGL2/TSH (upstream primer: 5'-CAGGATGT-TATGTGTATGGCTC-3' and downstream primer: 5'-CTTTAT-GTTTTGGCGTCTTC-3'). We employed the SYBR green system (Applied Biosystems) using an Applied Biosystems 7300 sequence detector. Relative values (mean \pm SD) normalized to input levels were compared with those obtained with control IgG.

Acknowledgment. We thank the NIH for financial support and L. Szewczuk for helpful suggestions.

JA909996P

(42) Kitz, R.; Wilson, I. B. *J. Biol. Chem.* **1962**, *237*, 3245–3249.